ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Regeneron Pharmaceuticals has agreed to acquire Checkmate Pharmaceuticals in a deal that values the Massachusetts-based firm at about $250 million. Checkmate’s lead drug candidate is vidutolimod, a biologic immune activator that stimulates T cells to attack tumors. It is delivered as a viruslike particle. In an announcement, Regeneron CEO Leonard S. Schleifer says he sees an opportunity to combine vidutolimod and other Checkmate compounds with Regeneron’s antibody-based oncology agents.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X